Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol

Pink urine syndrome is mostly seen in patients treated with propofol anesthesia. The pink color is attributed to the presence of large concentrations of uric acid (and pigment), which is excreted in large amounts when propofol is given. We describe a case of propofol-induced pink urine syndrome and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Bryan M., Perazella, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308841/
https://www.ncbi.nlm.nih.gov/pubmed/30596166
http://dx.doi.org/10.1016/j.ekir.2018.10.009
_version_ 1783383283580534784
author Tucker, Bryan M.
Perazella, Mark A.
author_facet Tucker, Bryan M.
Perazella, Mark A.
author_sort Tucker, Bryan M.
collection PubMed
description Pink urine syndrome is mostly seen in patients treated with propofol anesthesia. The pink color is attributed to the presence of large concentrations of uric acid (and pigment), which is excreted in large amounts when propofol is given. We describe a case of propofol-induced pink urine syndrome and perform a comprehensive, evidence-based review. We discuss prior case studies already published in the literature as we speculate on the pathophysiology and how it translates to a clinically relevant entity.
format Online
Article
Text
id pubmed-6308841
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63088412018-12-28 Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol Tucker, Bryan M. Perazella, Mark A. Kidney Int Rep Review Pink urine syndrome is mostly seen in patients treated with propofol anesthesia. The pink color is attributed to the presence of large concentrations of uric acid (and pigment), which is excreted in large amounts when propofol is given. We describe a case of propofol-induced pink urine syndrome and perform a comprehensive, evidence-based review. We discuss prior case studies already published in the literature as we speculate on the pathophysiology and how it translates to a clinically relevant entity. Elsevier 2018-10-13 /pmc/articles/PMC6308841/ /pubmed/30596166 http://dx.doi.org/10.1016/j.ekir.2018.10.009 Text en © 2018 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Tucker, Bryan M.
Perazella, Mark A.
Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title_full Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title_fullStr Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title_full_unstemmed Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title_short Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol
title_sort pink urine syndrome: a combination of insulin resistance and propofol
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308841/
https://www.ncbi.nlm.nih.gov/pubmed/30596166
http://dx.doi.org/10.1016/j.ekir.2018.10.009
work_keys_str_mv AT tuckerbryanm pinkurinesyndromeacombinationofinsulinresistanceandpropofol
AT perazellamarka pinkurinesyndromeacombinationofinsulinresistanceandpropofol

Ejemplares similares